Tore Bjerregaard Stage1,2, Magnus Graff1, Susan Wong3, Louise Ladebo Rasmussen1,4, Flemming Nielsen1, Anton Pottegård1, Kim Brøsen1, Deanna L Kroetz2, S Cyrus Khojasteh3, Per Damkier5,6,7. 1. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark. 2. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. 3. DMPK, Genentech, Inc., South San Francisco, CA, USA. 4. Mech-Sense, Department of Gastroenterology & Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg University, Odense, Denmark. 5. Department of Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark. 6. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 7. Odense Patient Data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
Abstract
AIM: The aim of this study was to study potential cytochrome P450 (CYP) induction by dicloxacillin. METHODS: We performed an open-label, randomized, two-phase, five-drug clinical pharmacokinetic cocktail crossover study in 12 healthy men with and without pretreatment with 1 g dicloxacillin three times daily for 10 days. Plasma and urine were collected over 24 h and the concentration of all five drugs and their primary metabolites was determined using a liquid chromatography coupled to triple quadrupole mass spectrometry method. Cryopreserved primary human hepatocytes were exposed to dicloxacillin for 48 h and changes in gene expression and the activity of CYP3A4, CYP2C9, CYP2B6 and CYP1A2 were investigated. The activation of nuclear receptors by dicloxacillin was assessed using luciferase assays. RESULTS: A total of 10 days of treatment with dicloxacillin resulted in a clinically and statistically significant reduction in the area under the plasma concentration-time curve from 0 to 24 h for omeprazole (CYP2C19) {geometric mean ratio [GMR] [95% confidence interval (CI)]: 0.33 [0.24, 0.45]}, tolbutamide (CYP2C9) [GMR (95% CI): 0.73 (0.65, 0.81)] and midazolam (CYP3A4) [GMR (95% CI): 0.54 (0.41, 0.72)]. Additionally, other relevant pharmacokinetic parameters were affected, indicating the induction of CYP2C- and CYP3A4-mediated metabolism by dicloxacillin. Investigations in primary hepatocytes showed a statistically significant dose-dependent increase in CYP expression and activity by dicloxacillin, caused by activation of the pregnane X receptor. CONCLUSIONS:Dicloxacillin is an inducer of CYP2C- and CYP3A-mediated drug metabolism, and we recommend caution when prescribing dicloxacillin to users of drugs with a narrow therapeutic window.
RCT Entities:
AIM: The aim of this study was to study potential cytochrome P450 (CYP) induction by dicloxacillin. METHODS: We performed an open-label, randomized, two-phase, five-drug clinical pharmacokinetic cocktail crossover study in 12 healthy men with and without pretreatment with 1 g dicloxacillin three times daily for 10 days. Plasma and urine were collected over 24 h and the concentration of all five drugs and their primary metabolites was determined using a liquid chromatography coupled to triple quadrupole mass spectrometry method. Cryopreserved primary human hepatocytes were exposed to dicloxacillin for 48 h and changes in gene expression and the activity of CYP3A4, CYP2C9, CYP2B6 and CYP1A2 were investigated. The activation of nuclear receptors by dicloxacillin was assessed using luciferase assays. RESULTS: A total of 10 days of treatment with dicloxacillin resulted in a clinically and statistically significant reduction in the area under the plasma concentration-time curve from 0 to 24 h for omeprazole (CYP2C19) {geometric mean ratio [GMR] [95% confidence interval (CI)]: 0.33 [0.24, 0.45]}, tolbutamide (CYP2C9) [GMR (95% CI): 0.73 (0.65, 0.81)] and midazolam (CYP3A4) [GMR (95% CI): 0.54 (0.41, 0.72)]. Additionally, other relevant pharmacokinetic parameters were affected, indicating the induction of CYP2C- and CYP3A4-mediated metabolism by dicloxacillin. Investigations in primary hepatocytes showed a statistically significant dose-dependent increase in CYP expression and activity by dicloxacillin, caused by activation of the pregnane X receptor. CONCLUSIONS:Dicloxacillin is an inducer of CYP2C- and CYP3A-mediated drug metabolism, and we recommend caution when prescribing dicloxacillin to users of drugs with a narrow therapeutic window.
Authors: D S Streetman; J F Bleakley; J S Kim; A N Nafziger; J S Leeder; A Gaedigk; R Gotschall; G L Kearns; J S Bertino Journal: Clin Pharmacol Ther Date: 2000-10 Impact factor: 6.875
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Anne Sandberg; Klaus Skovbo Jensen; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller Journal: Antimicrob Agents Chemother Date: 2010-03-22 Impact factor: 5.191
Authors: Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier Journal: Br J Clin Pharmacol Date: 2018-01-10 Impact factor: 4.335
Authors: Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier Journal: Br J Clin Pharmacol Date: 2018-01-10 Impact factor: 4.335
Authors: Herman Veenhof; Hugo M Schouw; Martine T P Besouw; Daan J Touw; Valentina Gracchi Journal: Eur J Clin Pharmacol Date: 2020-07-25 Impact factor: 2.953